Abstract
BackgroundCombined hepatocellular cholangiocarcinoma (cHCC-CC) is a rare form of primary liver tumor. A specific staging system for predicting survival in patients with cHCC-CC is not available. The aim of the present study was to evaluate the ability of staging systems and inflammation-based scores to predict overall survival (OS) and progression-free survival (PFS) of patients with cHCC-CC after surgical resection. MethodsThe data from 99 patients with cHCC-CC after surgical resection from June 2000 and January 2017 were retrospectively collected. Patients were allocated into HCC (hepatocellular carcinoma)—dominant (IHD) group and ICC (intrahepatic cholangiocarcinoma)—dominant (IID) group based on radiological characteristics. Similarly, patients were also divided into HCC-dominant (PHD) group and ICC-dominant (PID) group based on pathological characteristics. Univariate and multivariate analyses were performed to identify variables associated with OS and PFS. The prognostic value of staging systems and inflammation-based scores were analyzed and compared using receiver operating characteristic (ROC) curves. ResultsThe 1-, 2-, and 3-year OS rates were 82.6, 66.3, and 59.6%, respectively. The 1-, 2-, and 3-year PFS rates were 52.2, 38.1, and 31.5%, respectively. Independent prognostic factors identified by multivariate analyses included HCC-TNM staging system and tumor diameter both for OS and PFS analyses. HCC-TNM staging system displayed higher area under ROC curve (AUC) values than the other staging systems or inflammation-based scores. ConclusionsHCC-TNM staging system was able to adequately predict prognosis of patients with cHCC-CC after surgical resection, especially for patients with HCC-dominant characteristics in clinical practice.
Highlights
Combined hepatocellular carcinoma and cholangiocarcinoma, which contains elements of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) within the same tumor,[1] is a rare subtype that constitutesChaobin He and Yize Mao contributed to this work.0.4–14.2% of primary liver cancer cases.[2]
Over a 17-year period, between 2000 and 2017, 99 patients who were newly diagnosed with cHCC-CC and received surgical operation as the initial therapy in our hospital were included in the present study
There were 72 (72.7%) patients in the into HCC (hepatocellular carcinoma)—dominant (IHD) group and 27 (27.3%) patients in the imaging ICC-dominant (IID) group, whereas 61 (61.6%) patients were sorted into the patients were also divided into HCC-dominant (PHD) group and 38 (38.4%) patients were sorted into the pathological ICCdominant (PID) group
Summary
Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC), which contains elements of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) within the same tumor,[1] is a rare subtype that constitutesChaobin He and Yize Mao contributed to this work.0.4–14.2% of primary liver cancer cases.[2]. Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC), which contains elements of both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CC) within the same tumor,[1] is a rare subtype that constitutes. Chaobin He and Yize Mao contributed to this work. The aim of the present study was to evaluate the ability of staging systems and inflammation-based scores to predict overall survival (OS) and progression-free survival (PFS) of patients with cHCC-CC after surgical resection
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
